{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000136","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.565640+00:00","generated_at":"2026-05-17T09:13:52.364146+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025","bullets":["Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.","BCL2 inhibitor (BGB-11417) R&D spending surged to $94M from $39M YoY.","CDAC (BGB-16673) R&D increased to $27M from $6M; CDK4 (BGB-43395) to $10M from $2M.","Zanubrutinib R&D flat at $63M; Tislelizumab R&D up to $40M from $34M.","Filing includes PRC GAAP vs U.S. GAAP reconciliation for share-based comp, income taxes, leasing."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000136","json":"https://secwatch.observer/filing/0001651308-25-000136.json","markdown":"https://secwatch.observer/filing/0001651308-25-000136.md","text":"https://secwatch.observer/filing/0001651308-25-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/0001651308-25-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/bgne-20250829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:13:52.364146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}